StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The analyst's price forecast of $78 suggests substantial upside potential. Historical price movements following positive analyst coverage indicate trend alignments.
What happened, with direct paths to the underlying reporting
Tvardi completed its merger with Cara Therapeutics in April. The company’s lead drug, TTI-101, is in Phase 2 for IPF. Piper Sandler initiated coverage, rating TVRD as overweight with $78 target. TVRD is well-funded, expected to last into the second half of 2026. TTI-109, a next-gen drug, is also under development for STAT3.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.